Worldwide Ascites Market Highlights
Ascites or Peritoneal effusion refers to an excess collection of fluid in the abdominal cavity. There are quite a few risk factors that can cause this condition. However, high blood pressure is considered as the most common risk factor among all. A number of treatments are available to control fluid build-up and the associated symptoms effectively. Fluid analysis can help determine the cause, and a low-sodium diet and diuretics can help eliminate excess fluid.
Ascites treatment & management market is a well-developed space which is growing pervasively owing to the rising prevalence of blood pressure, liver cirrhosis, and portal hypertension along with the increasing incidences of heart and kidney failure, and cancers. Evidently, improving economic conditions worldwide are also one of the major factor increasing the market size of Ascites, increasing per capita healthcare expenditures and availing the quality care.
Get Exclusively Free Premium Sample Copy of Ascites Market Report @ https://www.marketresearchfuture.com/sample_request/1909 .
Favorable reimbursement policies along with the governmental initiatives such as programs for educating people on the management of Ascites are fostering the market growth. Increasing public and private funding support are impacting the market growth favorably, availing of novel effective treatments, surgeries, and medicines.
On the other hand, complications associated mainly with the serial large volume paracentesis (LVP), which is the first-line of treatment for refractory ascites, are expected to inhibit the market growth substantially. However, advancements happening in the biotechnology is expected to bring about some novel treatments that would help to eliminate any such complications.
Ascites Market – Segmentations
MRFR has segmented the report into five key dynamics for an easy grasp and enhanced understanding:-
By Types: Transudative, Exudate Ascites and Exudate Ascites among others.
By Treatments: Surgeries (peritoneovenous shunting, liver transplantation, transjugular intrahepatic portosystemic shunt (TIPS), and other surgeries), others.
By Diagnosis: Ultrasound, CT scan, Laparoscopy, and Angiography, others.
By End-Users : Hospitals, Clinics, Diagnostic Centers, and Ambulatory Surgical Centers, among others.
By Regions: North America, Europe, APAC and Rest-of-the-World (RoW).
The ultrasound segment by diagnosis is expected to acquire the largest as in 9% of the market share over the forecast period and is expected to register 4.4% CAGR during the assessment period 2017-2023
The exudate ascites segment by types is expected to command the largest as in 55.8% of the market share, registering 4.4% CAGR over the assessment period (2017-2023).
Key Players:
Market players driving the global ascites market include BioVie, Sequana Medical, PharmaCyte Biotech Inc., GI Supply, Fresenius SE & Co. KGaA, Medtronic plc., and Becton, Dickinson and Company. Profiling them in its analysis MRFR finds the strategies helping them to stay at the forefront of competition.
Global Ascites Market – Competitive Landscape
The competitive market for Ascites is fragmented with many large and small players operating in the market. Market players incorporate acquisition, collaboration, expansion, technology launch and strategic partnership. These players substantially invest in infrastructure development.
To help accelerate the treatment and to enhance patient’s experience, through the better understanding of the conditions, the diagnostic centers, and ambulatory surgical centers are collaborating with academia and the biotech industry to gain the help on the cutting-edge technologies. These collaborations are one of the strategies of market players by which they can leverage the scientific knowledge and translate it into innovative surgeries through partnering. These partnerships can kindle the innovative impulses that advance medicine and benefit patients as well as partners.
Industry/Innovation/Related News
June 12, 2018 – GI Supply (US), a leading global provider of innovative endoscopic (medical) products introduced an enhanced edition of the RenovaRP, a paracentesis management system. RenovaRP portable pump along with the redesigned Renova procedure kit expedites paracentesis procedures allowing medical professionals to treat patients safely, quickly, and cost-effectively. The RenovaRP pump is also effective for removing ascites fluid by gentle, continuous flow, taking less than 30 minutes, and without the need for evacuated bottles or canisters.
June 18, 2018 – Clover Biopharmaceuticals, Inc. (US), global, clinical-stage, research-based biotechnology company announced the initiation of the SCB-313 study for malignant ascites, marking the success and complete shift. In the Phase I trial, a dose of SCB-313, was administered to the first patient.
SCB-313 is an investigational fully-human TRAIL-Trimer fusion protein, which is effective in the treatment of cancer and malignant ascites.
In a scenario, where the treatment of malignant ascites remains a high unmet need globally, with no targeted or biologic antitumor therapies approved and available, the SCB-313 will provide a safe and efficacious option for patients worldwide.
Global Ascites Market- Regional Analysis
Globally North America region dominates the Ascites market with the significant market share and is expected to grow phenomenally from 2017 to 2023. Attributing to the favorable reimbursement scenario and higher expenditure on healthcare the market is expected to perceive a healthy growth. Besides factors such as availability of some well-developed technologies, high per capita healthcare expenditures, and the increasing prevalence of cirrhosis, which along with the presence of the leading players in the region help to substantiate the market growth. The market is expected to reach USD 1,292.2 Mn. by 2023
Europe emerging as a lucrative market for Ascites holds the second position in the market. Attributing to the increased funding and the support provided by the government and private entities for R&D and increasing number of surgeries the region is expected to expand, registering a phenomenal CAGR. Moreover, the resurging economy in the region is expected to foster the regional market growth, increasing healthcare expenditures. Also, the new improved reimbursement policies in healthcare are expected to fuel the Ascites market in Europe.
The Asia Pacific is growing rapidly, emerging as one of the lucrative markets for the management of Ascites. Rapidly advancing technology is increasingly meeting the demand of the huge patient pool resultantly driving the market growth in the region. Attributing to the increasing per capita healthcare expenditures, the region is expected to grow at a CAGR of 4.5% over the 2017-2023.
Get Discount @ https://www.marketresearchfuture.com/check-discount/1909 .
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Media Contact
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar
City: Pune
State: Maharashtra
Country: India
Website: https://www.marketresearchfuture.com/reports/ascites-market-1909